What is ThyroSeq and how can it help patients?
ThyroSeq® Genomic Classifier (GC) is a molecular test specifically designed to determine if a thyroid nodule is benign (not cancer) or malignant (cancer) when cytology result is indeterminate.
ThyroSeq also provides specific information about the genetic makeup of the nodule which allows physicians to determine an individualized course of treatment.
If a ThyroSeq result is negative, the patient can likely avoid surgical removal of their thyroid. If the result is positive, ThyroSeq provides additional information that helps the physician select the most appropriate surgery, which may include preserving part of the patient’s thyroid, protecting natural thyroid function.
For nodules with malignant cytology (Bethesda VI), ThyroSeq can help inform the extent of surgery and targeted therapy selection. For benign cytology nodules (Bethesda II) with clinical suspicion for malignancy, ThyroSeq may help clarify diagnosis.
Patient Management Using ThyroSeq
ThyroSeq test results refine cancer probability in thyroid nodules with indeterminate cytology, informing the most appropriate management of these patients.
ThyroSeq Utility for Prognostication and Therapy
Comprehensive molecular profiling by ThyroSeq provides preoperative prognostication of cancerous nodules, informing the extent of surgery and therapeutic options
ThyroSeq provides:
Preoperative assessment of the Risk of Cancer Recurrence (RCR)
Detection of clinically actionable therapeutic targets
Therapeutic gene targets (variants and fusions) detectable by ThyroSeq
How does ThyroSeq work?
The ThyroSeq test was designed by expert physicians in the field of thyroid cancer. The test combines years of scientific and clinical experience to help personalize patient care.
The leading platform for comprehensive genotyping of thyroid nodules
Interrogates 112 genes for four main classes of molecular alterations
Utilizes a proprietary Genomic Classifier (GC) that relies on the algorithmic analysis of all detected genetic alterations to report the test result as Positive or Negative
Results include a specific probability of cancer, potential management, and risk of recurrence
Validated in the largest prospective, double-blind, multicenter study of any commercially available molecular thyroid test
Highest NPV and PPV among well validated tests
Reliable detection of all types of thyroid tumors including Hürthle cell cancer, medullary thyroid cancer, and parathyroid lesions
ThyroSeq World-Wide Experience
The ThyroSeq test was designed by expert physicians in the field of thyroid cancer. The test combines years of scientific and clinical experience to help personalize patient care.
Yang Peiling S, et al. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules. Cancer Cytopathology. 2023. doi: 10.1002/cncy.22796.
Chen T, et al. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Healthcare Setting. Thyroid. 2020. doi: 10.1089/thy.2019.0539.
Rajab M, et al. Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada. Cancers. 2022. doi: 10.3390/cancers14174140.
Hier J, et al. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: A retrospective chart review. Journal of Otolaryngology - Head & Neck Surgery. 2021. doi: 10.1186/s40463-021-00500-6
Lévesque F, et al. Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience. The Journal of Clinical Endocrinology & Metabolism. 2024. doi: 10.1210/clinem/dgae355
How can I order ThyroSeq testing?
ThyroSeq testing is performed on an FNA biopsy, either freshly collected during an FNA procedure or on a previously made FNA cytology smear. Cell block and FFPE surgical tissue slides are also acceptable for ThyroSeq testing.
To set up ThyroSeq testing, please fill out the form. We will get back to you as soon as possible.
I understand that by checking the Consent box, I agree to UPMC’s EU Privacy Notice.
“Not accepting this ‘surgery to see’ for my daughter I came to discover ThyroSeq, a totally non-surgical solution in determining just what my daughter’s thyroid nodule was presenting. Following the test and assured by the most impeccable and flawless attention to us as clients, we received the best ever news that my daughter’s nodule was in fact Negative...the same result that a Thyroid Surgeon would have found had a partial Thyroidectomy been needlessly undertaken. We had prepared for a worse outcome but even then we were assured that ThyroSeq’s finding would have guided our own surgeon to perform a more targeted surgery if so needed.
To all at UPMC I cannot thank you enough for this truly impressive and indispensable tool called ThyroSeq. I urge all those presented with an indeterminate thyroid nodule result to not accept this ‘surgery to see’ and instead have your health ‘secured by science’ as ThyroSeq has so plainly proven for my daughter who has been spared the trauma of this standard surgical practice, the possibility of being medicated on in to the future and possible evidence of an operational scar following needless surgery.”